ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center
Research & Reviews 222 results
Cancer Medicine; Arakawa F, Miyoshi H et. al.
Sep 4th, 2021 - Telomere length is maintained by the activation of telomerase, which causes continuous cell division and proliferation in many carcinomas. A catalytic reverse transcriptase protein (TERT) encoded by the TERT gene plays a critical role in the activ...
Diagnostic Cytopathology; Tan B, Martin B et. al.
Aug 28th, 2021 - An 88-year-old man with end-stage renal disease on hemodialysis presented with shortness of breath and was found to have lower extremity edema and bilateral pleural effusions on a chest X-ray. A therapeutic and diagnostic thoracentesis was perform...
Blood Advani RH, Skrypets T et. al.
Jul 23rd, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018...
https://doi.org/10.1038/s41375-021-01321-2 10.1182/blood-2016-09-692541 10.1182/blood-2016-01-643569 10.1200/JCO.2011.37.3647 10.1038/s41375-020-0990-y 10.1097/MD.0b013e3181573059 10.1016/j.semcancer.2013.11.004 10.1038/ng.2873 10.1038/ng.2872 10.1038/ng.2916 10.1073/pnas.1617929114 10.1182/blood-2017-11-818617 10.1002/path.4898 10.1002/path.4920 10.1002/path.5376 10.1182/blood-2018-04-843714 10.1038/s41467-020-14919-4 10.1038/s41598-020-57741-0 10.1371/journal.pone.0177405 10.1002/eji.201242648 10.1016/j.celrep.2019.01.085 10.1038/nbt.2594 10.3389/fimmu.2019.01315 10.1016/j.cell.2018.11.043 10.1038/s41591-018-0057-z 10.1038/s41586-019-1836-5 10.1073/pnas.1913940117 10.1016/j.cyto.2014.11.010 10.3389/fimmu.2019.01088 10.1016/j.micinf.2011.10.003 10.3389/fimmu.2012.00014 10.1038/srep23505 10.1038/s41416-020-0757-2 10.1097/01.pai.0000173053.45296.51 10.1016/j.it.2013.11.001 10.1189/jlb.5A0816-346R 10.1371/journal.pone.0092009 10.1172/JCI79380 10.3960/jslrt.55.61
Leukemia Pritchett JC, Yang ZZ et. al.
Jul 8th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive lymphoid malignancy associated with a poor clinical prognosis. The AITL tumor microenvironment (TME) is unique, featuring a minority population of malignant CD4+ T follicular helper (TFH) ...
Current Opinion in Oncology; Tari G, Lemonnier F et. al.
Jul 8th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a frequent peripheral T-cell lymphoma affecting elderly patients with a poor outcome when treated with conventional chemotherapy. Molecular studies revealed a homogenous mutational landscape gathering a...
Clinicaltrials.gov 2 results
Jul 27th, 2018 - PRIMARY OBJECTIVES: I. To establish the maximum tolerated dose (MTD) of single agent carfilzomib in patients with relapsed and refractory peripheral T-cell lymphoma (PTCL) including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell ...
Jun 25th, 2018 - PRIMARY OBJECTIVES: I. To evaluate in a Phase II study a preliminary estimate of the complete response (CR) rate of a new chemotherapy regimen involving Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) alternating with Pralatrexate (...
News 20 results
Sep 11th, 2019 - Registries for T-cell lymphoma have improved our understanding of the disease, but many questions remain. Could combining the various registries provide more answers? “[T]here are many, many different registries around the world,” said Owen O’Conn.
Ermann DA, Vardell VA et. al.
Sep 9th, 2019 - Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive malignancy, representing approximately 18. 5% of Peripheral T-cell lymphomas.
Aug 9th, 2019 - LUGANO, SWITZERLAND – A combination of 5-azacytidine and romidepsin showed promising activity in patients with peripheral T cell lymphomas, particularly angioimmunoblastic T-cell lymphoma (AITL) and primary cutaneous follicular helper T-cell lymph.
Feb 6th, 2019 - LA JOLLA, CALIF. – The spleen tyrosine kinase/Janus kinase inhibitor cerdulatinib has demonstrated activity against relapsed and refractory T-cell lymphomas.
Feb 5th, 2019 - Efficacy with romidepsin Among all evaluable PTCL patients in the romidepsin arm, the ORR was 59% (16/27), and the CR rate was 33% (9/27). Responses occurred in seven patients with PTCL not otherwise specified (NOS), six with angioimmunoblastic T-.